Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
I-MAB ( (IMAB) ) just unveiled an update.
On October 24, 2025, shareholders of I-MAB approved a name change to NovaBridge Biosciences, which was officially filed on October 27, 2025. The company’s American Depositary Shares will trade under the new ticker symbol ‘NBP’ starting October 30, 2025. This rebranding reflects a strategic transformation to a global biotech platform, aiming to broaden access to capital and innovation through a planned dual listing on Nasdaq and the Hong Kong Stock Exchange. The company has also formed a new subsidiary, Visara, Inc., to focus on ophthalmic therapeutics, and continues to advance its core assets, including givastomig and VIS-101, in clinical trials.
The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
NovaBridge Biosciences, formerly known as I-MAB, is a global biotechnology platform company focused on accelerating access to innovative medicines. The company specializes in translational clinical development and business development to advance breakthrough assets. Its pipeline includes givastomig, a bispecific antibody for gastric cancer, and VIS-101, a biologic targeting VEGF-A and ANG2 for eye diseases.
Average Trading Volume: 2,744,790
Technical Sentiment Signal: Buy
Current Market Cap: $367.5M
See more insights into IMAB stock on TipRanks’ Stock Analysis page.